Evidence map›Paper›PMID 40198111›Full record

ArticleJMIR research protocols2025

Effectiveness of Stromal Vascular Fraction (SVF) and Platelet-Rich Plasma (PRP) in Patients With Knee Osteoarthritis: Protocol for a Phase 3, Prospective, Randomized, Controlled, Multicenter Study (SPOST Study).

Adrien Schwitzguebel, David Andres Ramirez Cadavid, Tamara Da Silva, Pierre Decavel, Charles Benaim

Registry-linked trialAbstract readClinical Trial Protocol
PubMed Full text at PMC Publisher
In one paragraph

Article in JMIR research protocols, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05660824 (Effectiveness of Stromal Vascular Fraction), which is not on this map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05660824 phase4not yet recruitingnot on this map

Effectiveness of Stromal Vascular Fraction (SVF) and Platelet -Rich Plasma (PRP) in Patients With Knee Osteoarthritis: Study Protocol for a Phase III, Prospective, Randomized, Controlled Multi-center Study : (SPOST Study)

TypeinterventionalSponsorAdrien SchwitzguebelRan2025 to 2027Enrolled108ConditionsOsteoarthritisArmsStromal Vascular Fraction infiltration, Plattelet Rich Plasma infiltration
3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Adrien Schwitzguebel *Sports Medicine Division, Hôpital de la Providence, Neuchâtel, Switzerland.ORCID 0000-0002-8212-1812
David Andres Ramirez Cadavid *Sports Medicine Division, Hôpital de la Providence, Neuchâtel, Switzerland.ORCID 0000-0001-9357-529X
Tamara Da SilvaGALSER SA, Neuchâtel, Switzerland.ORCID 0000-0002-4010-0992
Pierre DecavelFaculté des sciences et de médecine, University of Fribourg, Fribourg, Switzerland.ORCID 0000-0002-0567-7171
Charles BenaimPhysical Medicine and Rehabilitation division, Orthopedic Hospital, Centre Hospitalier Universitaire Vaudois, Laussanne, Switzerland.ORCID 0000-0002-8999-0674

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAvailable evidence on the conservative treatment of knee osteoarthritis still leaves questions about the efficacy of platelet-rich plasma (PRP) and whether stromal vascular fraction (SVF) offers a superior therapeutic tool.

objectiveThis study aims to assess the clinical efficacy of SVF as adjuvant therapy to PRP on functionality and tissue regeneration for knee osteoarthritis.

methodsIn a multicenter, randomized, triple-blind, controlled trial, 108 individuals with knee osteoarthritis will be block-randomized in a 1:1 ratio. Patients will receive an initial single PRP or PRP + SVF injection followed by PRP doses at 1 month and 2 months. The primary endpoint is functional improvement measured with the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) at the 6-month follow-up. Secondary endpoints, collected at the 1-month, 2-month, 3-month, 6-month, and 12-month follow-ups, will include the pain visual analogue scale during maximal physical activity, WOMAC score, length of time to return to work and sports in days, magnetic resonance imaging (MRI)-based Whole-Organ Magnetic Resonance Imaging Score (WORMS), Magnetic Resonance Observation of Cartilage Repair Tissue (MOCART) score, MRI Area Measurement and Depth and Underlying Structures (AMADEUS) score at 6 months and at 12 months, adverse events, and serious adverse events.

resultsParticipant recruitment and data collection are expected to begin in July 2025 and finish in July 2027. Final end points will be gathered in August 2027, and the results are expected to be published in late 2027.

conclusionsThe study results will provide insight into the clinical efficacy of SVF as adjuvant therapy to PRP on functionality and tissue regeneration in patients with knee osteoarthritis.

trial registrationClinicalTrials.gov (NCT05660824); https://clinicaltrials.gov/study/NCT05660824. INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID): PRR1-10.2196/62659.

Indexed as

Osteoarthritis, KneePlatelet-Rich PlasmaAdultAgedFemaleHumansMaleMiddle AgedMulticenter Studies as TopicProspective StudiesRandomized Controlled Trials as TopicTreatment Outcomeadjuvant therapyclinical efficacyosteoarthritisplatelet-rich plasmastromal vascular fractiontissue regeneration

Identifiers

PMID40198111
PMCPMC12015334

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.